Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.58 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.44 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.42 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.42 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.42 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.41 |
| ▸ | GALR3 | O60755 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | BLM | P54132 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.37 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.34 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | CTSK | P43235 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 3/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | HRH1 | P35367 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13773167 | 0.94 | TSHR (0.58) | TSHRTDP1CHRM2CHRM4CHRM1 | |
| SCHEMBL15430642 | 0.86 | TSHR (0.50) | TSHRTDP1CHRM2CHRM4CHRM1 | |
| SCHEMBL23311313 | 0.84 | TSHR (0.48) | TSHRTDP1CHRM2CHRM4CHRM1 | |
| SCHEMBL421627 | 0.84 | TSHR (0.48) | TSHRTDP1CHRM2CHRM4CHRM1 | |
| SCHEMBL14141296 | 0.82 | TSHR (0.46) | TSHRTDP1CHRM2CHRM4CHRM1 | |
| SCHEMBL19359816 | 0.80 | TSHR (0.44) | TSHRTDP1CHRM2CHRM4CHRM1 | |
| SCHEMBL421679 | 0.80 | TSHR (0.44) | TSHRTDP1CHRM2CHRM4CHRM1 | |
| SCHEMBL12967091 | 0.80 | TSHR (0.44) | TSHRTDP1CHRM2CHRM4CHRM1 | |
| SCHEMBL24186630 | 0.80 | TSHR (0.44) | TSHRTDP1CHRM2CHRM4CHRM1 | |
| SCHEMBL26636414 | 0.78 | TSHR (0.42) | TSHRTDP1CHRM2CHRM4CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 85 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101948713-A | Oenothera gracilis plant essential oil | TROPICAL CROPS GENETIC RESOURCES INST CHINESE ACADEMY OF TROPICAL AGRICULTURAL SCIENCES | 2011-01-19 | — | — | CN | claimed |
| US-20230151024-A1 | STING AGONISTIC COMPOUND | ONO PHARMACEUTICAL CO., LTD. (JP) | 2023-05-18 | — | — | US | disclosed |
| US-20230150941-A1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL AND PSYCHOLOGICAL DISORDERS | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2023-05-18 | — | — | US | disclosed |
| US-20230141284-A1 | CANCER THERAPEUTIC METHOD | ONO PHARMACEUTICAL CO., LTD. (JP) | 2023-05-11 | — | — | US | disclosed |
| CN-109952360-B | Quantum dot dispersion, self-luminous photosensitive resin composition, color filter manufactured using the same, and image display device | 东友精细化工有限公司 | 2022-03-22 | — | — | CN | disclosed |
| US-10040787-B2 | Prodrugs of NH-acidic compounds | ALKERMES PHARMA IRELAND LIMITED (IE) | 2018-08-07 | — | — | US | disclosed |
| US-10023537-B2 | Heterocyclic compounds for the treatment of neurological and psychological disorders | ALKERMES PHARMA IRELAND LIMITED (IE) | 2018-07-17 | — | — | US | disclosed |
| US-10011569-B2 | Process for synthesizing oxidized lactam compounds | ALKERMES PHARMA IRELAND LIMITED (IE) | 2018-07-03 | — | — | US | disclosed |
| US-20180162816-A1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL AND PSYCHOLOGICAL DISORDERS | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2018-06-14 | — | — | US | disclosed |
| US-20170267639-A1 | Process for Synthesizing Oxidized Lactam Compounds | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2017-09-21 | — | — | US | disclosed |
| US-20100120740-A1 | PRODRUGS OF FUSED HETEROCYCLIC INHIBITORS OF D-AMINO ACID OXIDASE | SEPRACOR INC. (US) | 2010-05-13 | — | — | US | disclosed |
| US-20100120740-A1 | PRODRUGS OF FUSED HETEROCYCLIC INHIBITORS OF D-AMINO ACID OXIDASE | SEPRACOR INC. (US) | 2010-05-13 | — | — | US | disclosed |
| US-20100056497-A1 | AMIDE DERIVATIVE | DAINIPPON SUMITOMO PHARMA CO., LTD (JP) | 2010-03-04 | — | — | US | disclosed |
| US-20100056497-A1 | AMIDE DERIVATIVE | DAINIPPON SUMITOMO PHARMA CO., LTD (JP) | 2010-03-04 | — | — | US | disclosed |
| US-7169899-B1 | Cyclic lactams comprising three amino acids and a tether chain to control the overall shape of the macromolecule; beta-turn mimetics to explore conformationally restricted structures; proteolytic enzyme resistance (nonhydrolyzing); cell penetration; anticoagulants; anticarcinogenic agents | TRANZYME PHARMA INC. (CA) | 2007-01-30 | — | — | US | disclosed |
| US-7169899-B1 | Cyclic lactams comprising three amino acids and a tether chain to control the overall shape of the macromolecule; beta-turn mimetics to explore conformationally restricted structures; proteolytic enzyme resistance (nonhydrolyzing); cell penetration; anticoagulants; anticarcinogenic agents | TRANZYME PHARMA INC. (CA) | 2007-01-30 | — | — | US | disclosed |
| US-7157411-B2 | Odor neutralizers | SYMRISE GMBH & CO. KG (DE) | 2007-01-02 | — | — | US | disclosed |
| US-20030068295-A1 | Odor neutralizers | SYMRISE AG (DE) | 2003-04-10 | — | — | US | disclosed |
| EP-1239890-A2 | ODOR NEUTRALIZERS | HAARMANN & REIMER GMBH (DE) | 2002-09-18 | — | — | EP | disclosed |
| WO-2001043784-A2 | ODOR NEUTRALIZERS | HAARMANN & REIMER GMBH (DE) | 2001-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230141284-A1 | CANCER THERAPEUTIC METHOD | STING1, CGAS, IFNAR1 | TSHR 1449/4885TDP1 1840/4885CHRM2 2732/4885 |
| US-20170267639-A1 | Process for Synthesizing Oxidized Lactam Compounds | COASY, DHPS, OXA1L | TSHR 4488/4885TDP1 4453/4885CHRM2 4012/4885 |
| US-10011569-B2 | Process for synthesizing oxidized lactam compounds | COASY, DHPS, OXA1L | TSHR 4488/4885TDP1 4453/4885CHRM2 4012/4885 |
| US-20030068295-A1 | Odor neutralizers | OXER1, OR51E2, OR10J3 | TSHR 1775/4885TDP1 3777/4885CHRM2 352/4885 |
| US-20180162816-A1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL AND PSYCHOLOGICAL DISORDERS | GABBR1, GABBR2, GABRE | TSHR 1280/4885TDP1 2311/4885CHRM2 1756/4885 |
| US-10023537-B2 | Heterocyclic compounds for the treatment of neurological and psychological disorders | GABBR1, GABBR2, GABRE | TSHR 1280/4885TDP1 2311/4885CHRM2 1756/4885 |
| US-10040787-B2 | Prodrugs of NH-acidic compounds | SI, NAAA, NIT2 | TSHR 3738/4885TDP1 3433/4885CHRM2 2676/4885 |
| US-20230150941-A1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL AND PSYCHOLOGICAL DISORDERS | GABBR1, GABBR2, GABRE | TSHR 1280/4885TDP1 2311/4885CHRM2 1756/4885 |
| US-20100120740-A1 | PRODRUGS OF FUSED HETEROCYCLIC INHIBITORS OF D-AMINO ACID OXIDASE | DDO, DAO, AOC1 | TSHR 2891/4885TDP1 1345/4885CHRM2 1780/4885 |
| US-20230151024-A1 | STING AGONISTIC COMPOUND | STING1, CGAS, TLR1 | TSHR 1797/4885TDP1 540/4885CHRM2 789/4885 |
| US-20100056497-A1 | AMIDE DERIVATIVE | REN, AGTR1, AGTR2 | TSHR 634/4885TDP1 4746/4885CHRM2 582/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.